Skip to main content
. 2021 Sep 24;26(19):5790. doi: 10.3390/molecules26195790

Figure 3.

Figure 3

The 5-HTr1A antagonist WAY-100635 (WAY) blocks the antidyskinetic effects of vilazodone. (A) Experimental design/timeline of study. (B,C) AIMs in 6-OHDA-lesioned rats treated with vehicle + L-DOPA (5 mg/kg, i.p.) (6/Veh/LD) in week 1, vilazodone (10 mg/kg, i.p.) + L-DOPA (6/VIL/LD) in week 2 and WAY-100635 (0.5 mg/kg, i.p.) + vilazodone + L-DOPA (6/W/VIL/LD) in week 3. The video analysis revealed that vilazodone co-administration (week 2) significantly attenuated the expression of AIMs compared to L-DOPA-only treatment (week 1), whereas WAY co-administration (week 3) significantly inhibited this beneficial effect of vilazodone treatment. This was shown for axial, limb and orolingual AIMs (individual animals) (B) and for total AIM scores (mean ± SEM) across 180 min after L-DOPA administration (C). *** p < 0.001, 6/VIL/LD vs. 6/Veh/LD; + p < 0.05, ++ p < 0.01, 6/W/VIL/LD vs. 6/VIL/LD. (D) Forelimb stepping scores (mean ± SEM) after these drug treatments. Neither vilazodone (6/VIL/LD) nor WAY (6/W/VIL/LD) had any effects on the L-DOPA-induced motor improvements (6/Veh/LD vs. baseline), as assessed by the forelimb stepping test. ### p < 0.001, vs. ipsilateral (INTACT) side; *** p < 0.001, vs. contralateral (LESION) baseline).